Cosmetics & Personal-Care (MoCRA) — regulation & compliance changes
Cosmetic and personal-care manufacturers and brands complying with FDA MoCRA — facility registration, product listing, safety substantiation, adverse-event reporting, and coming fragrance-allergen and PFAS rules — the first modern federal overhaul of cosmetics oversight.
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock so you never have to refresh a government page again. Every detected change becomes a plain-English briefing covering what changed, who it affects, what you must do, and by when. Forewarned is forearmed.
Stay ahead of every Cosmetics & Personal-Care (MoCRA) change
Real-time alerts, plain-English impact briefs, and a full searchable history — 100+ changes tracked in Cosmetics & Personal-Care (MoCRA) so far.
Get your compliance alert✓ No card charged during your trial · ✓ Cancel anytime · ✓ Every alert links to the official source
Recent changes in Cosmetics & Personal-Care (MoCRA)
- New Jersey bans some products with toxic PFAS chemicals. Here’s what to know - WHYY
- Implementing MoCRA: FDA Releases New Draft Guidances on Insanitary Conditions for Tattoo Ink and Cosmetic Product Registration & Listing - Food and Drug Law Institute (FDLI)
- France bans PFAS in cosmetics – COSlaw.eu - Guiding through EU Cosmetics Regulations - COSlaw.eu
- Illinois Governor Signs Bill Banning Intentionally Added PFAS in Certain Consumer Products and Requiring IEPA to Prepare Report on Fluoropolymers by August 1, 2027 - Bergeson & Campbell
- FDA Final Guidance on Cosmetic Facility Registration and Product Listing: Take Two - ArentFox Schiff
- FDA Launches Cosmetics Direct and Issues Final Guidance on Facility Registration & Product Listings Required under MoCRA - Crowell & Moring LLP
- Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA - retailconsumerproductslaw.com
- FDA drops proposed rule on asbestos testing in cosmetics - ConsumerAffairs
- FDA Withdraws Talc Asbestos Rule for Cosmetics - Environment+Energy Leader
- Reforming federal cosmetics law: What is the Modernization of Cosmetics Regulation Act? - EWG
- What to Watch For in 2026: A New Wave of PFAS Product Restrictions and Reporting Requirements Go Into Effect, with Many More Expected in 2027 and Beyond - Hunton Andrews Kurth LLP
- The Proliferation of State-level Regulation of PFAS in Consumer… - Kelley Drye & Warren LLP
- Landmark Cosmetic Law Adopted that Significantly Changes how Cosmetics Are Regulated by FDA - Steptoe
- Indonesia Proposes Regulation for "Non-Halal" Labeling on Cosmetics - CIRS Group
- How FDA is Implementing Landmark Cosmetics Legislation to Positively Impact Public Health - fda.gov
- Time’s Up! Cosmetic Facilities Must Comply With FDA’s New Registration Requirements by July 1 - Wiley Rein
- MoCRA Compliance: Key Legal Issues for Fashion Houses with Cosmetics - ArentFox Schiff
- FDA Issues New Cosmetics Proposed Rule: Let’s Talk About Talc - ArentFox Schiff
- Regulatory Trends and Compliance Strategies for PFAS in Cosmetics - CIRS Group
- FDA withdraws proposal to require talc-containing cosmetics to test for asbestos - The Hill
- A New Era of Cosmetics Safety Regulation - The Regulatory Review
- The FDA Withdraws Rule Requiring Asbestos Testing in Talc-Based Makeup - Vogue
- FDA withdraws proposed rule to test cosmetics made with talc for asbestos - Cosmetics Business
- The Trump Administration’s First Unified Agenda for FDA Promises Major Changes for the GRAS Pathway, Food Ingredients, and Cosmetics - The National Law Review
- Talc - fda.gov
- F.D.A. Withdraws Rule to Require Testing Cosmetics Made With Talc for Asbestos - The New York Times
- FDA poised to kill proposal that would require asbestos testing for cosmetics - The Guardian
- Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it? - The Cancer Letter
- U.S. Releases PFAS Regulation and Accountability Act of 2026, Phasing Out Non-Essential Uses Within 10 Years - CIRS Group
- FDA Withdraws Cosmetics Proposed Rule: Let Us (Not) Talk About Talc - ArentFox Schiff
- ‘Just crazy’: FDA facing backlash over withdrawal of proposed rule to screen some cosmetics for asbestos - The Hill
- Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA - Crowell & Moring LLP
- How MoCRA Is Reshaping FDA Oversight of Cosmetics in 2026 - Foley & Lardner LLP
- Talc Testing for Cosmetics: When Will FDA Issue a New Rule? - Mesothelioma.com
- Modernization of Cosmetics Regulation Act of 2022 (MoCRA) - fda.gov
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
- FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products
- FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
- FDA Advances Drug Repurposing to Address Unmet Medical Needs
- FDA Expands Sunscreen Options for the First Time in 20 Years
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
- FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
- FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
- FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
- FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
- FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
- FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
- FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health
- FDA Approves First Single-Dose Generic Treatment for Influenza
- FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
- FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
- Latex-containing Devices; User Labeling
- Cosmetics | FDA
- Surgeon's and Patient Examination Gloves; Reclassification
- Agency Information Collection Activities; Submission for OMB Review; Comment Request
- Agency Information Collection Activities: Proposed Collection; Comment Request; Reinstatement
- Agency Information Collection Activities; Proposed Collection; Comment Request; Cosmetic Product Voluntary Reporting Program
- Listing of Color Additives Exempt From Certification; Food, Drug, and Cosmetic Labeling: Cochineal Extract and Carmine Declaration
- Thymol; Exemption from the Requirement of a Tolerance
- Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Establishment of a Monograph
- Hazard Communication
- Air Fresheners; TSCA Section 21 Petition
- Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Web-Based Pilot Survey To Assess Allergy to Cosmetics in the United States
- Sunscreen Drug Products for Over-the-Counter Human Use
- Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph
- Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
- Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
- Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
- Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
- Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
- Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
- Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
- Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
- Medical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval System
- Medical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Test
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
- Establishment Registration and Product Listing for Tobacco Products
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
- Bifenthrin; Pesticide Tolerances
- Chlormequat Chloride; Pesticide Tolerances
- Diflufenican; Pesticide Tolerances
- Fluoxapiprolin; Pesticide Tolerances
- Epyrifenacil; Pesticide Tolerances
- Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic
- Termination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemic
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities-April 2026
- Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
- Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
Frequently asked questions
What does Aforeworn monitor for Cosmetics & Personal-Care (MoCRA)?
Aforeworn continuously tracks the official rules, ordinances, fee schedules and licensing requirements that affect Cosmetics & Personal-Care (MoCRA), detects every change, and explains in plain English what changed, who it hits and what to do.
How fast will I hear about a change in Cosmetics & Personal-Care (MoCRA)?
Changes are detected automatically as sources update, and subscribers are alerted in real time — often before the change is widely reported.
Why does staying current on Cosmetics & Personal-Care (MoCRA) matter?
A single missed change can mean fines, a lapsed licence, or lost eligibility. Forewarned is forearmed — knowing first lets you act before it costs you.